The Modified 5-Item Frailty Index as a Predictor of Postoperative Complications in Patients Undergoing Spinal Surgery. Performance Comparison at Different Levels of Surgical Complexity

改良版5项衰弱指数作为脊柱手术患者术后并发症预测指标:不同手术复杂程度下的性能比较

阅读:1

Abstract

Study DesignRetrospective cohort study.ObjectiveTo evaluate the predictive performance (discrimination and calibration) of the mFI-5 for major postoperative complications in thoracolumbar spine surgery, and to compare its effectiveness in low-, moderate-, and high-complexity procedures.MethodsThe study was conducted on adult patients (>18 years) who underwent thoracolumbar spine surgery at a single tertiary care center between 2017 and 2020. The primary outcome was the incidence of major complications within 90 days. Model discrimination was assessed using the area under the receiver operating characteristic curve (AUROC), and calibration was evaluated with calibration-in-the-large (CITL), calibration slope, and the Hosmer-Lemeshow test.ResultsA total of 839 patients were included (mean age: 62.8 years; SD: 16.8). Major complications occurred in 8.2% of cases. The mFI-5 demonstrated fair discrimination (AUROC: 0.66; 95% CI: 0.60-0.70) and excellent calibration (slope = 1, CITL = 0; Hosmer-Lemeshow P = .99). Stratified analysis showed improved discrimination in high-complexity surgeries (AUROC: 0.74; 95% CI: 0.64-0.84), compared to moderate (0.62; 95% CI: 0.48-0.74) and low complexity (0.63; 95% CI: 0.50-0.74) procedures. Readmission rates were 7% at 30 days and 9% at 90 days, with a 6-month mortality rate of 1%.ConclusionThe mFI-5 is a valuable tool for predicting major complications in thoracolumbar spine surgery, particularly in high-complexity procedures. Its predictive performance is limited in lower-complexity surgeries. Further prospective studies are needed to validate its use and enhance preoperative risk stratification.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。